Merck Ends Phase 3 Development of Investigational BTK Inhibitor Nemtabrutinib
Merck discontinues the clinical development of nemtabrutinib and all three Phase 3 BELLWAVE trials following a benefit-risk assessment that raised concerns about the investigational BTK inhibitor.
MSD | 20/11/2026 | By News Bureau
MSD's Capvaxive Receives Singapore HSA Approval for Adults Aged 18 and Above
MSD's Capvaxive receives Singapore HSA approval for active immunisation against invasive pneumococcal disease and pneumonia caused by 21 specified serotypes in adults aged 18 and above.
MSD | 30/10/2026 | By News Bureau | 131
SK bioscience, MSD and Hilleman Advance Ebola Vaccine with CEPI Funding
he collaboration will receive up to USD 30 million in CEPI funding to support development of MSD’s Zaire ebolavirus vaccine, with a focus on improving manufacturing efficiency, enhancing thermostability and expanding affordable vaccine access in low- and middle-income countries.
MSD | 23/01/2026 | By News Bureau | 296
ABL Bio Signs Clinical Alliance with MSD to Evaluate ABL103 with KEYTRUDA
Under the terms of the agreement, ABL Bio will conduct a phase 1b/2 clinical trial to evaluate the safety and efficacy of ABL103 in combination with KEYTRUDA. In this combination study, MSD will supply KEYTRUDA.
MSD | 07/10/2024 | By Aishwarya | 811
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy